The DOI matches its Crossref record; 218 of the 218 references it cites were found in a registry or an index.
Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances
Open accessAbstract
Chemotherapeutic agents have certain limitations when it comes to treating cancer, the most important being severe side effects along with multidrug resistance developed against them. Tumor cells exhibits drug resistance due to activation of various cellular level processes viz. activation of drug efflux pumps, anti-apoptotic defense mechanisms etc. Currently, RNA interference (RNAi) based therapeutic approaches are under vibrant scrutinization to seek cancer cure. Especially small interfering RNA (siRNA) and micro RNA (miRNA), are able to knock down the carcinogenic genes by targeting the mRNA expression, which underlies the uniqueness of this therapeutic approach. Recent research focus in the regime of cancer therapy involves the engagement of targeted delivery of siRNA/miRNA in combinations with other therapeutic agents (such as gene, DNA or chemotherapeutic drug) for targeting permeability glycoprotein (P-gp), Multidrug resistant protein 1(MRP-1), B-cell lymphoma (BCL-2) and other targets that are mainly responsible for resistance in cancer therapy. RNAi-chemotherapeutic drug combinations have also been found to be effective against different molecular targets as well and can increase the sensitization of cancer cells to therapy several folds. However, due to stability issues associated with siRNA/miRNA suitable protective carrier is needed and nanotechnology based approaches have been widely explored to overcome these drawbacks. Furthermore, it has been univocally advocated that the co-delivery of siRNA/miRNA with other chemodrugs significantly enhances their capability to overcome cancer resistance compared to naked counterparts. The objective of this article is to review recent nanocarrier based approaches adopted for the delivery of siRNA/miRNA combinations with other anticancer agents (siRNA/miRNA/pDNA/chemodrugs) to treat cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–218 of 218
Anionic amino acid-derived cationic lipid for siRNA delivery
Suh, M. S., Shim, G., Lee, H. Y., Han, S.-E., Yu, Y.-H., Choi, Y., Kim, K., Kwon, I. C., Weon, K.-Y., Kim, Y. B., et al. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.06.017 · Cited by 50
Jang, Y. L., Yun, U. J., Lee, M. S., Kim, M. G., Son, S., Lee, K., Chae, S. Y., Lim, D. W., Kim, H. T., Kim, S. H., et al. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.04.083 · Cited by 46
Wang, C., Fu, Y., Jian, S.-C., Wang, Y., Liu, P., Ho, M., & Wang, C. (2014) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2014.06.037 · Cited by 45
Interferência por RNA: uma nova alternativa para terapia nas doenças reumáticas
de França, N. R., Júnior, D. M., Lima, A. B., Pucci, F. V. C., Andrade, L. E. C., & da Silva, N. P. (2010) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042010000600008 · Cited by 44
Li, M., Lv, S., Tang, Z., Song, W., Yu, H., Sun, H. Y., Liu, H., & Chen, X. (2013) · Macromolecular Bioscience · doi:10.1002/mabi.201300222 · Cited by 43
Bai, S., Gupta, V., & Ahsan, F. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.07.002 · Cited by 40
Mangipudi, S. S., Canine, B., Wang, Y., & Hatefi, A. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800251x · Cited by 37
Guo, J., O’Mahony, A., Cheng, W. P., & O’Driscoll, C. M. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.02.050 · Cited by 36
Ramasubramanian, A. M., Shiigi, S. A., Lee, G., & Yang, F. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0406-9 · Cited by 27
Chen, S., Liu, X., GONG, W., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.2097 · Cited by 24
Zeng, S., & Xiong, M. P. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.05.010 · Cited by 22
Evaluation of pharmacological efficacy of ‘insulin–surfoplex’ encapsulated polymer vesicles
Rastogi, R., Anand, S., & Koul, V. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.01.022 · Cited by 22
Vittorio Cristini, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2118 · Cited by 17
Biocompatibility assessment of porous chitosan‐Nafion and chitosan‐PTFE composites in vivo
Liu, B., Ma, L., Su, J., Jing, W., Wei, M., & Sha, X. (2013) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.34830 · Cited by 15
Nishimura, G., Yanoma, S., Mizuno, H., et al. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00495-x · Cited by 14
Recent Patents in siRNA Delivery Employing Nanoparticles as Delivery Vectors
Nimesh, S. (2012) · Recent Patents on DNA & Gene Sequences · doi:10.2174/187221512801327406 · Cited by 9
Biodegradable Polymer-Mediated sh/siRNA Delivery for Cancer Studies
Jere, D., & Cho, C. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-588-0_16 · Cited by 5
Nanoparticle-Based Delivery of siRNA and miRNA for Cancer Therapy
(2012) · The Enzymes · doi:10.1016/b978-0-12-404741-9.00009-x · Cited by 4
Cited by
Nanostructured lipid carriers: Promising drug delivery systems for future clinics
Beloqui, A., Solinís, M. Á., Rodríguez-Gascón, A., Almeida, A. J., & Préat, V. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.09.004 · Cited by 769
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Liang, G., Zhu, Y., Ali, D. J., Tian, T., Xu, H., Si, K., Sun, B., Chen, B., & Xiao, Z. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0563-2 · Cited by 619
Composition design and medical application of liposomes
Li, M., Du, C., Guo, N., Teng, Y., Meng, X., Sun, H., Li, S., Yu, P., & Galons, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.007 · Cited by 555
siRNA Delivery Strategies: A Comprehensive Review of Recent Developments
Tatiparti, K., Sau, S., Kashaw, S., & Iyer, A. (2017) · Nanomaterials · doi:10.3390/nano7040077 · Cited by 429
Metadata
- Authors
- Gandhi, N. S., Tekade, R. K., & Chougule, M. B.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 194
- Pages
- 238-256
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2010731545
- Cited by
- 394
- References
- 218
- FWCI
- 17.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.